


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
TSRI 897.1SERIAL NO.  
10/527,525APPLICANT  
Markou, et al.FILING DATE  
10/14/2005GROUP  
1617INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

1	Waterhouse, et al., <u>Society for Neuroscience Abstracts</u> 27, No. 2: 2358 (2001)
2	Ahmed, et al., "Neurobiological Evidence for Hedonic Allostasis Associated with Escalating Cocaine Use", <u>Nature Neuroscience</u> 5, No. 7: 625-626 (2002)
3	Harrison, et al., "Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats", <u>Neuropsychopharmacology</u> 25, No. 1: 55-71 (2001)
4	Harrison, et al., "Nicotine Potentiation of Brain Stimulation Reward Reversed by DH $\beta$ E and SCH 23390, but not by Eticlopride, LY 314582 or MPEP in Rats", <u>Psychopharmacology</u> 160: 56-66 (2002)
5	Cryan, et al., "Bupropion Enhances Brain Reward Function and Reverses the Affective and Somatic Aspects of Nicotine Withdrawal in the Rat", <u>Psychopharmacology</u> 168: 347-358 (2003)
6	Shigemoto, et al., "Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus", <u>The Journal of Neuroscience</u> 17, No. 19: 7503-7522 (1997)

EXAMINER

DATE CONSIDERED